# A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

> **NCT03192345** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 161 (actual)

## Conditions studied

- Malignant Solid Tumor

## Interventions

- **BIOLOGICAL:** SAR439459
- **DRUG:** Cemiplimab REGN2810

## Key facts

- **NCT ID:** NCT03192345
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-09
- **Primary completion:** 2021-12-21
- **Final completion:** 2022-01-17
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192345, "A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03192345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*